TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24013497
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (0.05 mg/kg/day for 12 months)
Study: 19826305
Drug: Standard stretching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard stretching protocol (daily for 4 weeks, then discontinued)
Study: 11996943
Drug: Atorvastatin (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10-40 mg)
Study: 6680215
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment
Study: 10505027
Drug: Radiation or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation or chemotherapy alone
Study: 2371573
Drug: Diane contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane contraceptive pill
Study: 2371573
Drug: Microgynon 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgynon 50 contraceptive pill
Study: 30240471
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe)
Study: 27022625
Drug: Naloxone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone administration in healthy individuals
Study: 27022625
Drug: Naloxone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone administration in chronic pain patients
Study: 21505219
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and Vitamin D (1g calcium and 400 IU vitamin D daily)
Study: 10688158
Drug: Olanzapine 15
Normalized name: olanzapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 15 mg
Study: 13680082
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg doxepin (single i.v.)
Study: 13680082
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg doxepin (subchronic p.o.)
Study: 10584984
Drug: Prednisone 10
Normalized name: prednisone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 10 mg/day starting 1 month before ovulation induction for patients positive for ovarian autoantibodies (ov-ab).
Study: 10584984
Drug: Seronegative study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seronegative study group (no treatment).
Study: 17611232
Drug: Oral co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-amoxiclav
Study: 7787537
Drug: Intravenous followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous followed by oral co-amoxiclav
Study: 7787537
Drug: Intravenous followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous followed by oral cephalosporins
Study: 2081065
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy plus diazepam
Study: 2081065
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy alone
Study: 2081065
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy plus placebo
Study: 2081065
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (either alone or in combination)
Study: 30063297
Drug: Albiglutide 50
Normalized name: ALBIGLUTIDE 50MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 50 mg liquid formulation from an auto-injector (Regimen A)
Study: 30063297
Drug: Lyophilized albiglutide
Normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lyophilized albiglutide 50 mg from a DCC pen-injector (Regimen B)
Study: 22369287
Drug: vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin 50 mg qd
Study: 22369287
Drug: vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin 50 mg bid
Study: 17660482
Drug: vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin 100 mg qd
Study: 12678168
Drug: Zuclopenthixol acetate
Normalized name: zuclopenthixol acetate
DrugBank: Zuclopenthixol (DB01624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuclopenthixol acetate (ZPTA) 50-100 mg
Study: 12678168
Drug: Haloperidol (HAL)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol (HAL) 5-10 mg
Study: 7622272
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg at bedtime for 12 months
Study: 7622272
Drug: Macrocrystalline nitrofurantoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrocrystalline nitrofurantoin 50 mg at bedtime for 12 months
Study: 29233615
Drug: Higher HEI‐2010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher HEI‐2010 score in women with prior chemotherapy
Study: 24131168
Drug: Heroin administration
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin administration
Study: 23104147
Drug: Single-injection sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection sciatic nerve block combined with continuous femoral nerve block (group Fs)
Study: 16890834
Drug: fosamprenavir-ritonavir 700
Normalized name: fosamprenavir 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosamprenavir-ritonavir 700 mg/100 mg twice daily
Study: 16890834
Drug: lopinavir-ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir-ritonavir 400 mg/100 mg twice daily
Study: 15253741
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron administration (40 mg of saccharated ferric oxide after every dialysis session for four weeks)
Study: 15253741
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vehicle treatment)
Study: 11509476
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (2-hour)
Study: 16682305
Drug: Implantable cardioverter‐defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter‐defibrillator (ICD) therapy
Study: 3443058
Drug: Plain felodipine
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plain felodipine tablets, 10mg bid for 10 days
Study: 24955731
Drug: DHA diet
Normalized name: CHOLECALCIFEROL 0.25 mg in 1 g / CHONDRUS CRISPUS 350 mg in 1 g / ASCORBIC ACID 90 mg in 1 g TOPICAL CAPSULE [NIWEDAH BLACK SEED ASHWAGANDHA DIETARY SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA diet supplementation (1.14 g per day for eight weeks)
Study: 18201893
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (15 ml bolus, 10 ml every 6h)
Study: 18201893
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% (20 ml bolus, 15 ml every 6h)
Study: 15323595
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg/day
Study: 1902159
Drug: Active nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nitroglycerin patches (mean necessary effective patch dose: 125 sq cm, range 60 to 220 sq cm)
Study: 27753201
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg/d) for 12 weeks
Study: 27178766
Drug: Single testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single testosterone injection
Study: 22147468
Drug: Inoculated silage
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculated silage (IN) with mixed bacterial culture (1.0 × 10(11) cfu/g Lactobacillus buchneri LN4017, 2.0 × 10(10) cfu/g Lactobacillus plantarum LP7109, 1.0 × 10(10) cfu/g Lactobacillus casei LC3200)
Study: 17292954
Drug: Nabumetone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (2 g or 1 g for 11 patients)
Study: 26018634
Drug: Meloxicam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (15 mg)
Study: 9621139
Drug: pH5 Eucerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH5 Eucerin aftersun lotion with 10% hamamelis distillate
Study: 9621139
Drug: Other lotions
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other lotions (vehicle and prior aftersun formulation)
Study: 3280325
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin plus colistin (V/C)
Study: 15281530
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin (AVP) infusion (4 U/h)
Study: 15281530
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) infusion alone
Study: 11951146
Drug: Delta(9)-THC (5.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta(9)-THC (5.0, 7.5 or 10.0 mg)
Study: 2477096
Drug: 7.5% NaCl/Dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% NaCl/Dextran 70 solution
Study: 30617461
Drug: l-bupivacaine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-bupivacaine (12.5 mg h−1) continuous wound infusion for 48 hours via a pre-sternal multiperforated catheter
Study: 30617461
Drug: l-bupivacaine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-bupivacaine (12.5 mg h−1) continuous wound infusion for 48 hours
Study: 21250913
Drug: rHuEPOα therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPOα therapy (300 IU/kg/dose, 3 times/week, subcutaneously)
Study: 21250913
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rHuEPOα therapy)
Study: 9595999
Drug: Femoral injection
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral injection of echo contrast medium
Study: 9595999
Drug: Femoral injection
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral injection of echo contrast medium plus Valsalva maneuver
Study: 9595999
Drug: Ante cubital
Normalized name: wood ant preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ante cubital injection of echo contrast medium
Study: 9595999
Drug: Ante cubital
Normalized name: wood ant preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ante cubital injection of echo contrast medium plus Valsalva maneuver
Study: 1761875
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 7.5 mg
Study: 3035166
Drug: Salt and
Normalized name: ZINC OXIDE 240 mg in 1 g TOPICAL STICK [Salt and Stone Outdoor Voices SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt and peroxide oral hygiene regimen
Study: 2536410
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral hygiene methods
Study: 27436543
Drug: 6.5-mm hydrophilic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5-mm hydrophilic implants placed with osteotome sinus floor elevation (OSFE)
Study: 27436543
Drug: Standard implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard implants placed with lateral sinus floor elevation
Study: 27436543
Drug: Long implant
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implant group
Study: 23736112
Drug: Indapamide sustained-release
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide sustained-release 1.5mg
Study: 15719741
Drug: Weitai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weitai capsule (WTC), 4 capsules, 3 times a day for 3 months
Study: 10510988
Drug: IV unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV unfractionated heparin (UFH) - loading dose: 5000 U IV; initial infusion, 1250‐1280 U/h
Study: 7718899
Drug: CY‐TBI (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY‐TBI (120 mg/kg of cyclophosphamide followed by total body irradiation)
Study: 7718899
Drug: BU‐CY (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: BU‐CY (16 mg/kg of busulfan followed by 120 mg/kg of cyclophosphamide)
Study: 7718899
Drug: MoAb (anti‐interleukin‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoAb (anti‐interleukin‐2 receptor monoclonal antibody)
Study: 2391395
Drug: SCH 39304
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 39304 with antacid
Study: 6792073
Drug: Parenteral diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral diet (1.5 g amino acid . kg‐1 . d‐1 and 7.6 g carbohydrate kg . d‐1)
Study: 6792073
Drug: Increased carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased carbohydrate infusion (1.5 g amino acids . kg‐1 . d‐1 and 12 g carbohydrate . kg‐1 . d‐1)
Study: 6792073
Drug: Two-fold amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-fold amino acid intake (3.0 g . kg‐1 . d‐1 and 7.6 g carbohydrates . kg‐1 . d‐1)
Study: 31663981
Drug: 10-μg estradiol
Normalized name: estradiol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-μg estradiol (E2) softgel vaginal insert
Study: 31663981
Drug: 25-μg estradiol
Normalized name: estradiol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-μg estradiol (E2) softgel vaginal insert
Study: 26170395
Drug: 4 repeated
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 repeated doses of albendazole
Study: 26170395
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of albendazole
Study: 16289984
Drug: Physiogel cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiogel cream (control)
Study: 15127991
Drug: Tapered Brånemark
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapered Brånemark System Mark IV fixture (97 implants)
Study: 15127991
Drug: Brånemark Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brånemark Standard or Mark II implants (92 implants)
Study: 15127991
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Mark IV and control implants)
Study: 11038030
Drug: Once-weekly schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly schedule of 5-fluorouracil and L-folinic acid
Study: 11038030
Drug: Four-weekly schedule
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-weekly schedule of 5-fluorouracil and L-folinic acid
Study: 1356646
Drug: Atracurium (ATR)
DrugBank: Atracurium (DB13295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atracurium (ATR) - loading dose 0.25 mg.kg‐1, infusion at 5.0 micrograms.kg‐1.min‐1
Study: 1356646
Drug: Vecuronium (VEC)
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium (VEC) - loading dose 0.05 mg.kg‐1, infusion at 1.0 microgram.kg‐1.min‐1
Study: 3910768
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg administered 1 hour before a standardized breakfast
Study: 3910768
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg administered together with a standardized breakfast
Study: 3910768
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 2 weeks prior to captopril
Study: 27537754
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g IV paracetamol
Study: 27537754
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g oral paracetamol
Study: 27537754
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g oral paracetamol
Study: 22854666
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg hepatitis B vaccine
Study: 22854666
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose at year 23
Study: 12622499
Drug: Tramadol 20
Normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 20 mg intravenous bolus via patient-controlled analgesia device
Study: 12622499
Drug: Morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2 mg intravenous bolus via patient-controlled analgesia device
Study: 10676043
Drug: Raloxifene, specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene, specific dosage and duration not available
Study: 7547044
Drug: Peritonsillar infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar infiltration with tenoxicam 5 mg in 8 ml of normal saline (4 ml per tonsil)
Study: 1778925
Drug: Caffeine (CAF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (CAF, 9 mg/kg)
Study: 6754118
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin ethyl succinate (paediatric dosage)
Study: 6754118
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% tetracycline ointment
Study: 30572905
Drug: Levofloxacin (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (15-20 mg/kg daily for six months)
Study: 27573335
Drug: Tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer with the Breathing Easier Support Toolkit (BEST)
Study: 22213304
Drug: Vinorelbine (oral)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (oral) 60 mg/m² on days 1, 8, 15 every 4 weeks for 4 cycles (group A)
Study: 22213304
Drug: Paclitaxel (intravenous)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (intravenous) 90 mg/m² for 1 h on days 1, 8, 15 every 4 weeks for a total of 4 cycles (group B)
Study: 20145555
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) training at 35 Hz for 5 minutes twice a week
Study: 12106923
Drug: LDL-A group
Normalized name: meningococcal group A polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group A (DB13889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-A group (medication + LDL-A, n = 11)
Study: 12106923
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (medication only, n = 7)
Study: 1858944
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion (0.855 M, 0.06 ml.min‐1.kg‐1)
Study: 1858944
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline infusion (0.154 M, 0.06 ml.min‐1.kg‐1)
Study: 1858944
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion (0.855 M)
Study: 31174494
Drug: Mobile phone
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone app-based cognitive behaviour training (CBT) for 6 weeks, with weekly theme modules including learning content and assignments.
Study: 25152290
Drug: Coopdech bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coopdech bronchial blocker (group A)
Study: 22873532
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (maintenance therapy)
Study: 21209539
Drug: Volume preload
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume preload of 1000 ml of Ringer's lactate solution
Study: 2691479
Drug: Amoxycillin/clavulanate (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (1,000 mg amoxycillin + 250 mg clavulanate) tds
Study: 2691479
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg) bd
Study: 6154334
Drug: Hypothermic cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic cardioplegic solution (200-1000 ml) infused into the ascending aorta during cardiopulmonary bypass.
Study: 31764793
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide (1 mg, 4 ml) for 15 minutes before bronchoscopy
Study: 26946208
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intraoral device or treatment)
Study: 22714779
Drug: Topical (S)-ketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical (S)-ketamine
Study: 16225527
Drug: Transdermal oxybutynin
Normalized name: oxybutynin Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oxybutynin (1.3, 2.6, and 3.9 mg/day)
Study: 16225527
Drug: Transdermal oxybutynin
Normalized name: oxybutynin Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oxybutynin (3.9 mg/day)
Study: 16225527
Drug: Extended-release tolterodine
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tolterodine (4 mg/day)
Study: 10068415
Drug: Daily intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravenous infusion of 60 microg of prostaglandin E1 (alprostadil‐alpha‐cyclodextrine)
Study: 10744344
Drug: rHuEPO (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (all doses)
Study: 1959538
Drug: rHuEPO (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (doses greater than 25 units/kg)
Study: 6955123
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction and practice in proper toothcleaning techniques